Triptorelin: The Dual-Action GnRH Superagonist
Last updated: March 2026
Triptorelin (Decapeptyl) is a GnRH superagonist with ~100× higher receptor affinity than native GnRH. A single ultra-low dose exploits the initial LH/FSH flare for HPTA reset after AAS. Repeated depot doses cause medical castration — used for prostate cancer, endometriosis, and precocious puberty.
🧪 Buy Triptorelin at Swiss Chems →Single SC Injection
Oncology Depot Dose
Prostate Cancer Rx
📋 On this page
How Triptorelin Works
Triptorelin has a paradoxical dose-dependent biphasic action — it stimulates at first, then profoundly suppresses. Understanding this pharmacology is essential: the same molecule that resets the HPTA at 100 mcg will shut it down at 3.75 mg monthly.
Upon first binding GnRH receptors, triptorelin causes an immediate burst of LH and FSH — the "flare" — lasting 1–3 days. LH can increase 4–10× above baseline. This flare is the mechanism exploited in PCT use: a single 100 mcg SC injection fires the suppressed pituitary-gonadal axis back to life, potentially jumpstarting recovery after prolonged AAS suppression.
With continued GnRH agonist exposure (as in monthly depot injections), pituitary GnRH receptors are continuously occupied and downregulate. This leads to uncoupling from intracellular signaling, loss of LH/FSH secretion, and subsequent testosterone fall to castration levels (<50 ng/dL) within 2–4 weeks. This phase is the therapeutic mechanism for prostate cancer.
The theoretical PCT use (100 mcg single SC injection) leverages only Phase 1. The short half-life of the injected peptide means receptor occupancy is brief — enough to fire the flare but not enough to cause sustained downregulation. Published case reports (Buvat et al.) show testosterone recovery within 3 months. However, controlled RCT data is lacking.
For prostate cancer androgen deprivation therapy (ADT), triptorelin 3.75 mg IM monthly or 11.25 mg IM quarterly maintains continuous receptor desensitization. Combined with an anti-androgen for the first 2–4 weeks (to block the initial testosterone flare in oncology patients), it achieves long-term medical castration, reducing prostate cancer growth driven by testosterone.
What the Clinical Trials Show
Data from prostate cancer ADT trials and available PCT case literature. Note: high-quality RCT data for PCT use is essentially absent — most evidence is case series and anecdotal.
Side Effects & Risks
Key Takeaways
- Triptorelin causes an initial LH/FSH flare (1–3 days) then suppression with continued use
- Single 100 mcg SC injection exploits flare phase for PCT HPTA restart
- 3.75 mg IM monthly achieves testosterone castration (<50 ng/dL) in ~94% of prostate cancer patients
- FDA-approved (Trelstar) for prostate cancer and precocious puberty
- PCT use is off-label and based primarily on case series, not RCTs
- Anti-androgens must accompany oncology dosing to prevent symptom flare from initial testosterone surge
- No RCTs comparing triptorelin PCT to standard SERM PCT protocols
- Optimal timing window for PCT injection post-AAS cessation
- Whether triptorelin PCT offers meaningful advantage over clomiphene/enclomiphene PCT
- Long-term reproductive outcomes after triptorelin PCT in bodybuilding populations
🛒 Recommended Products
Monitoring supplies for post-cycle therapy and hormone tracking.
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational purposes only. It is not medical advice. Triptorelin is a prescription drug (Trelstar/Decapeptyl) requiring a licensed healthcare provider. Off-label PCT use is not FDA-approved and lacks controlled trial data. The oncology dosing information is for educational reference only. Never self-administer prescription GnRH agonists. Consult a qualified physician before any hormonal protocol.